SUZHOU, China--(BUSINESS WIRE)--MabSpace Biosciences announced that on August 24^th, 2018, MSB2311 was successfully administered to the first Chinese cancer patient at Beijing Cancer Hospital in its China Phase 1 trial. MSB2311 is a 2^nd-generation PD-L1 antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration.

“Our mission at MabSpace is to provide cancer patients with superior and affordable antibody-based therapeutics. The successful completion of dosing of MSB2311 into the first Chinese cancer patient is an important milestone for us,” said Xueming Qian, Ph.D., Founder, Chairman and CEO, MabSpace Biosciences. “We will advance this program into registration trial next year. In addition, we will also initiate combination trials early next year with MSB2311 as the backbone.”

MSB2311 is the first product candidate derived from MabSapce’ pipeline generated using its immune tolerance breaking technology platform. MabSpace has 12 ongoing programs in its R&D pipeline. On August 28th, 2018, Mabspace submitted another IND application to NMPA for MSB0254, the second product candidate from the platform. “We will continue to move at least one more innovative biologics asset in our pipeline per year into clinical stage to meet patients’ needs,” added Xueming Qian.

MSB0254 is a novel humanized VEGFR2 antibody which antagonizes both VEGF-A and VEGF-C mediated tumor-associated angiogenesis, an important pathway utilized by tumor cells for growth and metastasis. A VEGFR2 blocking antibody in the same class has been approved in US for the treatment of 2^nd line gastric cancer, NSCLC, and CRC and recently shown to have benefits in a subset of 2^nd line HCC patients. MSB0254 will be developed for these cancer types and may also serve as an important combination therapy with PD-1/PD-L1 inhibitors such as MSB2311.

About MabSpace Biosciences

MabSpace Biosciences Co., Ltd. is a private, venture-backed biotechnology company specialized in discovering and developing innovative antibody therapeutics using its proprietary immune tolerance breaking technology platform. MabSpace has built up a pipeline in immune-oncology, ophthalmology as well as nephrology. The immune-oncology (IO) pipeline is spearheaded by MSB2311, and includes molecules targeting various pathways regulating tumor immune cycle as well as multiple targeted antibodies. MabSpace is headquartered in Hong Kong, with a fully-integrated antibody discovery and development facility in Biobay, Suzhou Industrial Park, China.

Contacts

MabSpace Biosciences Co., Limited
Kathy YUAN, +86-512-67079200-8008
kathy.yuan@mabspacebio.com